While the evolutionary nature of cancer is well established, it is challenging to generate and analyze data to quantify the dynamics of this Darwinian process. The clinical issue is for example when therapy-resistant cancer cells regrow after an initially successful treatment. Hence, patients die because the tumor is able to evolve. Hematologic neoplasms such as leukemia and lymphoma are well suited to study this process, because live cells can be sampled and studied in detail over the course of the disease. To better understand and eventually influence this process, it is necessary to measure the amount of genetic and epigenetic heterogeneity. New technologies to characterize genetic and phenotypic heterogeneity at the single cell level render it possible to tackle this issue.
Your Opportunities and Responsibilities
- Work on an exciting project that bridges genomics, evolutionary theory and oncology and will strengthen your profile in a field of great scientific and medical relevance
- Investigate heterogeneity of hematologic neoplasms on the single cell level.
- Optimize established transcriptional single cell technologies (Fluidigm C1, SCRB-seq, Drop-seq) and make them available to collaborations within the CRC. This includes the molecular techniques as well as first analyses.
- Improve and extend the existing single cell technologies to combine RNA-seq, DNA-seq and ATAC-seq.
- The CRC enables you to work in a highly multidisciplinary environment with cutting edge technologies in the field of genomics and cancer research.